About Event:

The Best of Hematology and Breast Cancer 2025 conference in Boise is a CME-accredited, in-person event providing healthcare professionals with the latest s in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting ASH24 and the San Antonio Breast Cancer Symposium SABCS24, the conference features expert presentations on recent research and its clinical implications. Focusing on a multidisciplinary approach, the event aims to integrate new advancements into patient-centered care. Designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other professionals, attendees will engage with colleagues and experts to critically evaluate data and improve patient outcomes. LEARNING OBJECTIVES Summarize the latest s from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer. Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24. Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH24 and SABCS24 that have influenced current standards of care. Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH24 and SABCS24 into patient management for hematologic disorders and breast cancer. Apply emerging data from clinical trials and d expert guidelines from ASH24 and SABCS24 to individualize patient management strategies.